Medicare Enrolled

Dr. Amir Agha, MD

Rheumatology · Decatur, GA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
1435 MCLENDON DR STE AANDB, Decatur, GA 30033
7702843150
In practice since 2006 (20 years)
NPI: 1730144114 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Agha from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Agha? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Agha

Dr. Amir Agha is a rheumatology specialist in Decatur, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Agha performed 137,907 Medicare services across 1,237 unique beneficiaries.

Between the years covered by Open Payments, Dr. Agha received a total of $58,246 from 38 pharmaceutical and/or device companies across 822 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Agha is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 8% volume in GA $58,246 industry payments

Medicare Practice Summary

Medicare Utilization ↗
137,907
Medicare services
Top 8% in GA for rheumatology
1,237
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,895 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
57,110 $11 $45
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
53,600 $4 $13
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
12,500 $33 $60
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
5,810 $26 $100
Denosumab injection (Prolia/Xgeva) 3,900 $17 $22
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
1,638 $85 $150
Joint lubricant injection (Durolane)
An injection of hyaluronan or its derivative, specifically Durolane, administered directly into a joint space.
780 $5 $20
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
682 $84 $250
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
673 $8 $25
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
322 $19 $75
Betamethasone steroid injection
An injection containing a combination of betamethasone acetate and betamethasone sodium phosphate.
304 $5 $55
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
266 $51 $100
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
144 $46 $130
New patient office visit, complex (60-74 min) 74 $150 $300
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
65 $10 $50
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
25 $65 $110
Tendon or ligament injection
A procedure involving the injection of medication into a tendon or ligament.
14 $43 $120
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
55.2% high complexity
43.1% medium
1.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$58,246
Total received (2018-2024)
Avg $8,321/year across 7 years
Top 7% in GA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
822
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$47,544 (81.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,776 (16.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$926 (1.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,532
2023
$1,607
2022
$1,603
2021
$4,085
2020
$5,423
2019
$26,834
2018
$17,162

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$321
ABBVIE INC.
$200
UCB, Inc.
$199
Novartis Pharmaceuticals Corporation
$152
PFIZER INC.
$144
Janssen Biotech, Inc.
$95
AstraZeneca Pharmaceuticals LP
$83
Organon Llc
$71
US Oncology Corporate, Inc.
$54
Celgene Corporation
$44
Bioventus LLC
$38
Boehringer Ingelheim Pharmaceuticals, Inc.
$32
Radius Health, Inc.
$31
Azurity Pharmaceuticals, Inc.
$19
Medtronic, Inc.
$18
Genentech USA, Inc.
$18
Mallinckrodt Hospital Products Inc.
$14
Top 3 companies account for 47.0% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$23,903
Amgen Inc.
$10,217
AbbVie, Inc.
$7,756
Novartis Pharmaceuticals Corporation
$7,613
Janssen Biotech, Inc.
$2,035
UCB, Inc.
$1,637
PFIZER INC.
$871
E.R. Squibb & Sons, L.L.C.
$428
Regeneron Healthcare Solutions, Inc.
$362
Mallinckrodt Hospital Products Inc.
$302
Lilly USA, LLC
$293
AstraZeneca Pharmaceuticals LP
$289
Horizon Therapeutics plc
$265
GlaxoSmithKline, LLC.
$260
Janssen Scientific Affairs, LLC
$256
ABBVIE INC.
$215
Aurinia Pharma U.S., Inc.
$157
AbbVie Inc.
$145
Boehringer Ingelheim Pharmaceuticals, Inc.
$134
Antares Pharma, Inc.
$126
ANI Pharmaceuticals, Inc.
$124
Organon LLC
$90
Mallinckrodt Enterprises LLC
$87
Alexion Pharmaceuticals, Inc.
$86
Genentech USA, Inc.
$82
Organon Llc
$71
Bioventus LLC
$70
Horizon Pharma plc
$64
US Oncology Corporate, Inc.
$54
Radius Health, Inc.
$45
Merck Sharp & Dohme Corporation
$41
Exeltis, USA Inc.
$41
ARBOR PHARMACEUTICALS, INC.
$30
MEDEXUS PHARMA, INC.
$24
Mallinckrodt LLC
$20
Azurity Pharmaceuticals, Inc.
$19
Medtronic, Inc.
$18
BOSTON SCIENTIFIC CORPORATION
$18
Top 3 companies account for 71.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · DUEXIS · Durolane · EVENITY · EVUSHELD · Enbrel · FORTEO · GENERAL PAIN MANAGEMENT · HADLIMA · Horizant · Humira · INTELLIS ADAPTIVESTIM · KEVZARA · KEVZARA SARILUMAB INJECTION · KRYSTEXXA · LUPKYNIS · LYRICA · OFEV · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · STELARA · STRENSIQ · SUPARTZ FX SODIUM HYALURONATE · Strensiq · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · Tavneos · Tremfya · Tymlos · VIMOVO · XELJANZ · XYOSTED
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for rheumatology in GA.

Looking for a rheumatology specialist in Decatur?
Compare rheumatologists in the Decatur area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
88
Per 100K population
11.5
County median income
$77,683
Nearest hospital
EMORY DECATUR HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Agha is a mixed practice specialist, with above-average Medicare volume (top 8% in GA), with speaking/promotional industry engagement in the top 7% of GA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Agha experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Agha performed 57,110 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Agha receive payments from pharmaceutical companies?
Yes. Dr. Agha received a total of $58,246 from 38 companies across 822 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Agha's costs compare to other rheumatologists in Decatur?
Dr. Agha's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Agha) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →